U.S. Hospitality Stock News

Virtu Financial recently declared a quarterly cash dividend of US$0.24 per share, confirmed for payment on December 15, 2025 to shareholders of record as of December 1, and reported third quarter 2025 earnings with revenue of US$824.79 million and net income of US$77.63 million, both higher than the prior year period. Alongside these results, the company completed a tranche of its multi-year share repurchase program, signaling continued focus on returning capital to shareholders through both...

Citigroup (C) has entered into a strategic alliance with Coinbase to develop new digital asset payment capabilities for institutional clients, expanding its footprint in the evolving crypto payments landscape. This collaboration aims to make fiat and digital asset transactions more seamless by combining Citi's global payments network and Coinbase's blockchain technology expertise. Investors will be watching to see how this move shapes Citi's broader digital transformation strategy. See our...

Sequans Communications (SQNS) is currently unprofitable, but has managed to reduce losses by 42.6% per year over the past five years. Revenue is expected to grow 25.61% annually, well ahead of the US market average growth rate of 10.5%. However, the company is still forecast to remain in the red over the next three years. Investors looking at the setup will see attractive top-line growth prospects and a price-to-sales ratio of 2.7x, which is notably lower than the semiconductor industry...

Caribou Biosciences (CRBU) is attracting fresh attention after releasing positive interim data from phase 1 trials of its lead CAR-T therapies, vispacabtagene regedleucel and CB-011, for lymphoma and multiple myeloma. See our latest analysis for Caribou Biosciences. Momentum has picked up for Caribou Biosciences following its positive clinical trial updates and upcoming pivotal studies, but recent volatility is hard to ignore. The stock’s 1-day share price return dropped 10.7% after the data...

Compass (COMP) remains unprofitable, but over the last five years the company has steadily narrowed its losses by an average of 21.1% each year. Looking forward, earnings are forecast to grow at a rapid 61.21% per year, with analysts expecting Compass to reach profitability within the next three years. With annual revenue projected to grow at 10.8%, outpacing the broader US market’s 10.5% estimate, the equity story for Compass is tilted toward rewards due to anticipated strong profit and...

If you have ever found yourself wondering if Sarepta Therapeutics is undervalued or poised for a rebound, you are not alone. Let's dig into whether this moment presents an opportunity or a warning sign. The stock has seen sharp moves recently, dropping 33.1% in just the last week and losing nearly 87% of its value over the past year. This volatility follows headlines around regulatory delays and shifts in biotech investor sentiment, which have sparked heated debates about the company's...

Wondering if Evercore could be a bargain or if the market has already priced in its prospects? You are not alone, especially with all the noise surrounding this stock lately. Over the past year, Evercore shares have risen 10.8%, with an impressive 195.6% gain over three years. However, recent weeks have seen some pullback as the stock is down 7.5% in the past 7 days and 9.6% for the month. Much of this recent movement can be traced to broader market volatility and sector-specific news, such...

Curious whether Antero Midstream is a hidden value play or just another stock with a flashy ticker? Here is a breakdown of the story to get to the bottom of what it might be worth. Despite recent turbulence, with the share price down 2.4% over the past week and off 10.0% for the month, Antero Midstream is still up an impressive 11.0% year-to-date and has surged 24.1% over the past year. A series of positive analyst upgrades and renewed interest in energy infrastructure stocks have fueled...

Wondering if TriMas is trading for less than it's worth? You're not alone, as investors are always keen to spot undervalued opportunities before the market catches on. TriMas has seen some sharp moves lately, with the stock dropping 11.1% over the last week and 10.7% in the past month, even though it's still up 41.3% year-to-date. Market watchers are buzzing about recent industry developments and shifting economic conditions that are shining a spotlight on companies like TriMas. These...

Genius Sports (GENI) continues to operate at a loss, but over the last five years, it has managed to cut annual losses by 26%. While the company remains unprofitable, analysts project impressive earnings growth of 100.48% per year and expect profitability within three years. With revenue forecast to climb 15% annually, which is higher than the broader US market forecast of 10.5%, investors have a front-row seat to a transition story fueled by rapid top-line expectations and progressively...

Curious whether Marsh & McLennan Companies is a bargain or overhyped? You are not alone, and getting the valuation right could make all the difference. Despite a slight 1.3% dip over the last week, the stock has pulled back further by 10.3% this month and is down 14.6% year-to-date, following a 17.2% slip over the past year. Yet, look beneath the surface and the company has delivered 72.7% gains over the last five years. This suggests both past strength and shifting sentiment. In recent...

Ever wondered if Universal Health Services could be quietly trading at a bargain, or if the price is already running ahead of itself? Let’s dig into what the numbers and market signals are really telling us. The stock has had a strong year so far, climbing 24.8% year-to-date with recent momentum pushing it up another 8.2% over the last month alone. Shares have been in focus lately after the company expanded its behavioral health network and landed new managed care agreements. These...

CompoSecure (CMPO) remains unprofitable, with net losses deepening at a rate of 66.8% per year over the past five years. Still, analysts forecast earnings to grow 168.7% annually and expect the company to cross into profitability within the next three years. Revenue is projected to climb 37.6% a year, which far outpaces the US market average of 10.5%. See our full analysis for CompoSecure. The next section examines how these headline numbers align with well-known market narratives,...

Denny's (DENN) net profit margin slipped to 2.2% from last year's 3.9%, with annual earnings declining by 11.9% over the past five years and recent negative growth that makes year-on-year comparisons tough. Investors may be watching closely as revenue is only expected to grow at 3.4% per year, lagging well behind the broader US market’s projected 10.5%. However, despite these lackluster trends and a relatively rich valuation, forecasts are calling for a sharp rebound in earnings, with a...

Sanmina (SANM) posted standout numbers, with revenue expected to surge by 31.3% per year and earnings forecast to grow at 30.8% annually, both outpacing the broader US market’s pace. The company’s profit margins ticked up slightly to 3%, and earnings momentum has accelerated. Annual growth ran at 4.8% over the past five years and came in at 10.5% last year, while projections show greater than 20% annual earnings growth ahead. Investors are likely to see this rapid expansion in both top and...

IAC (IAC) posted another unprofitable year as losses accelerated by 35.7% per year over the last five years, with revenue expected to decline by 11.2% annually for the next three years. Despite the challenging recent performance, earnings are forecast to rebound strongly by 69.09% per year, and the company is expected to turn profitable within three years, even as the share price sits at $32, below the estimated fair value of $36.08. See our full analysis for IAC. The next section will...

Wondering if Ameren is trading at a bargain, or if the price is already reflected in its valuation? Let’s dig into what really drives the company’s value. Ameren’s share price has pulled back slightly this month, slipping 1.8% in the last 30 days. Over the last year, the stock is up a solid 19.7%, and it has gained 43.0% over five years. Recent headlines have put Ameren in the spotlight for its strategic grid modernization investments and increased focus on sustainable energy. There has also...

Ocular Therapeutix (OCUL) is projected to grow revenue by a rapid 52.8% per year, far outpacing the US market average of 10.5%. Despite the impressive growth outlook, the company posted increased annual losses of 22.7% per year over the last five years and is expected to remain unprofitable for at least the next three years. The stock is currently priced at $10.90, which is significantly below its estimated fair value of $25.23 based on discounted cash flow analysis. However, it trades at a...

Norwegian Cruise Line Holdings (NCLH) posted net profit margins of 6.8%, up from 5.9% last year, showing clear margin improvement. Earnings have grown rapidly at 59.2% per year over the past five years. Forward-looking estimates see earnings increasing another 37.9% per year. Even as this outpaces the broader US market, revenue growth forecasts of 8.6% per year trail the US average of 10.5%. While investors will note a recent one-off loss of $272.5 million that hit results, the stock looks...

Williams Companies (WMB) posted net profit margins of 20.4% for the recent period, down from last year’s 27.8%. Although earnings are forecast to grow at 13.53% annually, this is slower than both the US market average of 16% and the broader oil and gas industry. The current share price of $56.51 sits below an estimated fair value of $75.76. With a Price-to-Earnings ratio of 29.2x, WMB trades at a significant premium to its peers. Investors will note strong historical earnings growth over the...

Kymera Therapeutics (KYMR) posted another unprofitable year, with annual losses growing at a rate of 28.4% per year over the past five years. The company’s margins remain under pressure, and analysts expect revenue to contract by roughly 2.5% annually over the next three years. Shares are currently trading at $59.91. With profitability still out of reach and revenue momentum fading, the numbers highlight the continued financial headwinds for Kymera. See our full analysis for Kymera...

Adeia (ADEA) posted a net profit margin of 19.3%, up from last year's 12%. Annual earnings are forecast to grow at 7.02%. Over the past year, earnings increased by 77.7%, significantly outpacing the company's five-year average of -13.4% per year. These results reflect the impact of improved margins and accelerating growth on investor sentiment, as shareholders balance attractive valuation multiples with non-recurring losses and closely monitor the company’s financial quality. See our full...

Riot Platforms reported record third-quarter 2025 earnings, with revenue rising to US$180.23 million and net income reaching US$104.48 million, driven mainly by strong Bitcoin mining and the production of 1,406 Bitcoin. The company also announced the initiation of 112 megawatts of development at its Corsicana, Texas data center campus, highlighting a significant pivot towards diversified data center operations for AI and high-performance computing. We’ll explore how Riot’s progress in data...

Vital Farms (VITL) reported earnings forecasted to grow at 18.02% annually, with revenue projected to rise by 19.2% per year, both outpacing the broader US market. Net profit margins now stand at 8.5%, just below last year's 8.7%, while recent annual earnings growth reached 21.1%. Over the past five years, average yearly earnings growth has been an impressive 54.5%. See our full analysis for Vital Farms. The real test is how these results stack up against the broader narratives shaping market...